Clinical Trial

PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma

Study acronym: FIL_PRIORITY
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The final analysis of GHSG HD11 study (not PET driven) showed that 30 Gy IFRT still remains the standard dose after 4 ABVD. Early PET negativity might allow safe radiation de-escalation in patients achieving a metabolic complete response after 2 ABVD. The aim of Priority trial is to explore whether radiotherapy could be safely deescalated to 20 Gy without loss of efficacy in patients treated with four cycles of ABVD who achieved complete metabolic response after the first two cycles.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Trial Details
NCT Number NCT07256158
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions Hodgkin Lymphoma
Enrollment 518 participants
Start Date 2026-03-01
Primary Completion 2033-03-01 (estimated)
Study Completion 2033-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-09